New Alzheimer’s disease screening test performs well in UK outpatient settings

**QUESTION**

**Question:** How effective is the TYM (‘test your memory’) cognitive test in detecting Alzheimer’s disease?

**Patients:** 159 people attending a memory clinic: 31 people with non-Alzheimer’s degenerative dementias, 108 people with Alzheimer’s disease or amnestic mild cognitive impairment (85 with National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association criteria diagnosis and 23 with amnestic mild cognitive impairment). 94 people (mean age 69 years) were included in the analysis for Alzheimer’s disease as nine people with amnestic mild cognitive impairment scored poorly on the Addenbrooke’s Cognitive Examination-revised (ACE-R) and were regarded as likely to progress to Alzheimer’s disease. The 14 remaining people with amnestic mild cognitive impairment were analysed separately. People with cognitive problems caused by depression were excluded. 540 control participants aged 18–95 years were recruited from relatives taking people to the memory clinic, medical outpatients from two other hospitals and some dermatology outpatients. People with memory problems, a history of neurological or brain injury were excluded.

**Setting:** Three hospital outpatient departments, Cambridge; March–December 2007.

**Test:** The TYM (http://tymtest.com/) comprises 11 tasks: orientation (10 points), semantic knowledge (3 points), verbal fluency (4 points), naming (6 points), ability to copy a sentence (2 points), calculation (4 points), similarities (4 points), visuospatial abilities (two tasks, total 7 points) and recall of a copied sentence (6 points). Ability to do the test is the final task and scored 5 points. Total score (maximum 50) is calculated by adding the scores together. The TYM is presented on double sided card, with spaces for users to complete the test.

**Diagnostic standard:** ACE-R, that includes the Mini-Mental State Examination (MMSE)

**Outcomes:** Sensitivity, specificity, positive predictive value and negative predictive value.


**METHODS**

**Design:** Diagnostic cohort study.

**MAIN RESULTS**

Mean TYM score of control participants was 47/50. Mean TYM score of participants with Alzheimer’s disease was 33/50. Mean TYM score of participants with non-Alzheimer’s dementias was 39/50. There were significant correlations between all scores in patients with Alzheimer’s disease (TYM vs MMSE, R²=0.51, p<0.01; TYM vs ACE-R, R²=0.66, p<0.01; ACE-R vs MMSE, R²=0.770, p<0.001). Three age matched controls (n=282) were randomly selected for each patient with Alzheimer’s disease and used to calculate a receiver operating curve (see table). A TYM score cut-off of ≤42 predicts mild Alzheimer’s disease with a sensitivity of 93% and specificity of 86%. Assuming a 10% prevalence of Alzheimer’s disease and a cut-off ≤42, the positive predictive value of the TYM was 42% and the negative predictive value 99%. The TYM had greater sensitivity for detecting Alzheimer’s disease compared with the MMSE (93% vs 52%).

**Table Receiver operating curve analysis for detection of Alzheimer’s disease using the ‘test your memory’ cognitive test**

<table>
<thead>
<tr>
<th>Score</th>
<th>Sensitivity</th>
<th>False negative rate</th>
<th>Specificity</th>
<th>False positive rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤45</td>
<td>97</td>
<td>3</td>
<td>75</td>
<td>25</td>
</tr>
<tr>
<td>≤44</td>
<td>96</td>
<td>5</td>
<td>81</td>
<td>19</td>
</tr>
<tr>
<td>≤43</td>
<td>94</td>
<td>6</td>
<td>83</td>
<td>17</td>
</tr>
<tr>
<td>≤42</td>
<td>93</td>
<td>7</td>
<td>86</td>
<td>14</td>
</tr>
<tr>
<td>≤41</td>
<td>87</td>
<td>13</td>
<td>91</td>
<td>9</td>
</tr>
<tr>
<td>≤40</td>
<td>83</td>
<td>17</td>
<td>92</td>
<td>8</td>
</tr>
<tr>
<td>≤39</td>
<td>81</td>
<td>19</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>≤38</td>
<td>75</td>
<td>25</td>
<td>96</td>
<td>4</td>
</tr>
</tbody>
</table>

**CONCLUSIONS**

TYM is a valid new screening test for detecting Alzheimer’s disease.

**ABSTRACTED FROM**


**Correspondence to:** J Brown, Department of Neurology, Addenbrooke’s Hospital, Cambridge CB2 2QG, UK; jmb75@medschl.cam.ac.uk

**Source of funding:** Alzheimer’s Research Trust (UK), Cambridge Commonwealth Trust, Stroke Association.

It remains to be seen where this measure will find its niche as a clinical tool. The Department of Health has a strategy to encourage the early diagnosis of dementia with a view to improving the quality of ongoing care. The TYM may assist patients’ care pathway so long as it is used with caution as one component of the initial clinical investigation and subsequent monitoring. We would like to see formal testing in a wider range of illnesses, and we need more clinical experience with this new instrument, but in our own ward and clinics, it looks like the days of the MMSE are numbered.

Sameer Jauhar, MRCPsych
Anthony Pelosi, FRCPsych
Hairmyres Hospital, East Kilbride, UK

**Competing interests:** None